Amgen to acquire Rodeo Therapeutics in $721m worth deal
Amgen has agreed to acquire Rodeo Therapeutics, a Seattle-based biopharma company, in a deal worth up to $721 million. Rodeo Therapeutics is engaged in developing ... Read More
Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab
Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 billion, to add ... Read More
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with the National Medical Products Administration (NMPA) in ... Read More
Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies
Eli Lilly and Company has entered into a global antibody manufacturing collaboration with Amgen to considerably boost the supply capacity for its potential COVID-19 therapies. ... Read More
Janssen, Amgen secure FDA approval for DKd regiment in multiple myeloma
DKd regiment FDA approval for multiple myeloma : Janssen Pharmaceutical Companies of Johnson & Johnson and Amgen have been granted an expanded approval from the ... Read More
Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798
Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics License Application (BLA) to the US Food ... Read More
Bristol-Myers Squibb wraps up $74bn acquisition of Celgene
Bristol-Myers Squibb has wrapped up its $74 billion acquisition of Celgene having got regulatory approval from all government authorities necessary for closing the merger agreement ... Read More
FTC clears decks for Bristol-Myers Squibb acquisition of Celgene
Bristol-Myers Squibb acquisition of Celgene : US pharma giant Bristol-Myers Squibb said that the US Federal Trade Commission (FTC) has given its clearance for its ... Read More
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn
US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per ... Read More
CANDOR clinical trial results : Amgen’s Kyprolis extends PFS in multiple myeloma patients
CANDOR clinical trial results : Amgen said that a phase 3 study assessing Kyprolis (carfilzomib) in combination with dexamethasone and Johnson & Johnson's Darzalex (daratumumab) ... Read More